Hansa Biopharma interim report January–March 2023
· Positive reimbursement decision in Spain expands market access to include the five largest European markets · Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed · HNSA-5487: Phase 1 clinical study started in healthy volunteersLund, Sweden, April 20, 2023, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to March 2023. Highlights for the first quarter of 2023 · Total Q1 revenue of SEK 24.2m including SEK 14.3m in product sales